Table 2. Selection of ongoing clinical trials evaluating epigenetic targeted therapies in hematologic malignancies.
| Clinical Trial | Intervention | Malignancy studied |
|---|---|---|
| EZH2 inhibitors | ||
| NCT02395601 | Phase 1 Study: EZH2 inhibitor CPI-1205 | Progressive B-cell lymphomas |
| NCT01897571 | Phase 1/2 Study: EZH2 inhibitor E7438 | B-cell lymphomas and advanced solid tumors |
| KDM inhibitors | ||
| NCT02261779 | Phase 1/2 Study: ATRA + tranylcypromine (TCP) an irreversible monoamine-oxidase (MAO) and Lysin-specific demethylase (LSD) inhibitor | Relapsed/refractory AML |
| IDH2 inhibitors | ||
| NCT01915498 | Phase 1/2 Study: reversible inhibitor of mutant IDH2 AG-221 | Advanced hematologic malignancies with IDH2 mutation |
| NCT02273739 | Phase 1/2 Study: reversible inhibitor of mutant IDH2 AG-221 | Advanced solid tumors (glioma) and angioimmunoblastic T-cell lymphoma |
| BET1/DOT1L inhibitors | ||
| NCT01943851 | Phase 1/2 Study: BET inhibitor GSK525762 | Relapsed/refractory hematologic malignancies (leukemias, myeloproliferative neoplasms, lymphomas, and myelomas) |
| NCT02158858 | Phase 1 Study: BET inhibitor CPI-0610 | AML, myelodysplastic syndromse, myeloproliferative neoplasms, myelofibrosis |
| NCT02308761 | Phase 1 Study: BET inhibitor TEN-010 | AML, myelodysplastic syndromse |
| NCT01684150 | Phase 1 Study: second generation DOT1L inhibitor EPZ-5676 | AML/ALL/MLL with MLL1 rearrangements (including 11q23 or partial tandem duplications) in adult patients |
| NCT02141828 | Phase 1 Study: second generation DOT1L inhibitor EPZ-5676 | AML/ALL with MLL1 rearrangements (including 11q23 or partial tandem duplications) in pediatric patients |
| Combination treatment with cancer vaccines | ||
| NCT01483274 | Phase 1 study: Decitabine + donor lymphocyte infusion + Vaccine (autologous dendritic cells) | AML with relapse after allogeneic stem cell transplantation |
| Combination treatment with immune checkpoint inhibitors | ||
| NCT02281084 | Phase 2 Study: Durvalumab (PD-L1 inhibitor) + CC-486 (oral azacitidine) | Myelodysplastic syndromes |
| NCT02530463 | Phase 2 Study: Nivolumab (PD-1 inhibitor) and/or Ipilimumab (CTLA-4 inhibitor) + azacitidine | Myelodysplastic syndromes |
This list is not complete but presents a selection of clinical trials by the authors of this manuscript meant to illustrate the different strategies.